Clin-Dev-Fig-6-1

Young Investigator Award

Dedicated to identifying new talent in the immunosequencing field

Every quarter, Adaptive Biotechnologies selects one or more applicants for our Young Investigator Award to receive a grant of up to $10,000 to assist in their research.

submit a project proposal

Current recipients 2021

Johanna Grund, Department of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Germany

Classical Hodgkin lymphoma (cHL) is a common malignancy of the lymphatic system. The malignant cells are called Hodgkin-Reed-Sternberg cells (HRSC) and comprise only 1-3% of all cells in the neoplastic lymph nodes. However, HRSC are surrounded by a variety of immune cells such as T cells, B cells, and macrophages which build up a unique tumor microenvironment. Even though cHL has a high cure rate, patients suffer from long-term toxicity due to the intensive chemotherapy. Therefore, the aim of this research project is to identify prognostic and predictive factors in order to better understand the immune repertoire and allow for future risk-adapted treatment and/or replace chemotherapy by targeted drugs such as immune checkpoint therapy (ICT).

Application Deadlines & Award Announcements

Applications are accepted and reviewed on a quarterly basis.

Quarter 1 application deadline: March 31st - Award winner announced the first week of May.
Quarter 2 application deadline: June 30th - Award winner announced the first week of August. 
Quarter 3 application deadline: September 30th - Award winner announced the first week of November.
Quarter 4 application deadline: December 31st - Award winner announced the first week of February. NOW ACCEPTING APPLICATIONS

Magalli Magnoumba Legnanga, PhD student,
Africa Health Research Institute

Asmae Gassa, MD,
University of Cologne

Eriomina Shahaj, PhD,
Fondazione IRCCS Instituto Nazionale Dei Tumori

Coco de Koning, PhD,
University Medical Center Utrecht

Braden Tarlow, MD, PhD,
Stanford University Medical Center

Rachel Ambler, PhD,
The Francis Crick Institute

Kellie Nunez, PhD,
Ochsner Health System

Amelie Jule, PHD
Boston Children's Hospital

Andrew Gunderson, PhD
Providence Portland Medical Center

Sruthi Ravindranathan, PhD
Emory University

Ronald Paranal, MD
MD Anderson Cancer Center

Emilie Foord, PhD
Karolinska Institute

Hussein Abbas, MD, PhD
MD Anderson Cancer Center

Swadhinya Arjunaraja, PHD
Uniformed Services University of the Health Sciences

Rachel Howard PhD
Lee Moffitt Cancer Center

Heather McGee, MD, PhD
Icahn School of Medicine at Mount Sinai

Lucas Arruda, PHD
Karolinska Institute

Dr. Med. Filiz Oezkan
The Ohio State University

Roy Rabbie, MBCHB (HONS), M.SC., MRCP
Wellcome Trust Sanger Institute, Cambridge

Jessica Stokes
University of Arizona

Timothy Taxter, MD
Northwestern University

Kathryn Steel, PhD
Kings College London Instituiton

Clinton Yam, MBBS
MD Anderson Cancer Center

James Godfrey, MD
University of Chicago

Lauren Colbert, MD
MD Anderson Cancer Center

Sami Kanaan, PhD
Fred Hutchinson Cancer Research Center

Benson Ogunjimi, PhD
University of Antwerp

Tiago R. Matos, MD, MSC, PhD
Academic Medical Center, University of Amsterdam

Ruth J. Napier, PhD
Oregon Health Science University

Isha Pradhan, PhD
Allegheny Health Network

Boglarka Ujhazi, MS
University of South Florida

Koorosh Korfi, PhD
Queen Mary University, London

Amy O'Connel, MD, PhD
Boston Children's Hospital

Kate Poropatich, MD
Northwestern University Medical School

Tin Wang
University of Washington

Shwetank, PhD
Pennsylvania State University College of Medicine

Esteban Arrieta-Bolanos, PhD
Institute For Experimental Cellular Therapy, Essen University Hospital

Letizia Amadori, PhD
Icahn School Of Medicine At Mount Sinai

Matteo Dugo, M. Sc.
Fondazione Irccs Istituto Nazionale Dei Tumori

Adhideb Ghosh, M. Sc.
University Zürich Hospital

Ashley Plant, MD
Dana Farber Cancer Institute, Children's Hospital Boston

Swati Shree, MD
University Of Washington Medical Center

Andreas Agathangelidis, PhD
Istituto Scientifico San Raffaele

Sarah Baxter, MD, PhD
Seattle Children's Hospital

Catherine W. Cai
Saint Louis University School of Medicine

Georg J. Furtmüller, MD
Istituto Scientifico San Raffaele

Thet Su Win, MD, PhD
Brigham and Women's Hospital

Justin Drerup
University Of Texas Health Science Center At San Antonio

Alexandre Reuben
University Of Texas Md Anderson Cancer Center

Joseph Thome
Columbia University

Fransenio Clark, BS
University Of Massachusetts Medical School

Laura Cook, PhD
University Of British Columbia, Child And Family Research Institute

Mathias Stiller
German Cancer Consortium

Mélissa Mathieu
Centre De Recherche Du Chum, Institut Duccancer De Montréal

Amy Moran, PhD
Earle A Chiles Cancer Research Institute

Jillian Richmond, PhD
University Of Massachusetts Medical School

Spyros Chalkias
Beth Isreal Deaconess Medical Center

Iwona Konieczna
Northwestern University

Elisa Masat
University Pierre And Marie Curie, Inserm U974

Reeta Vanhanen
Haartman Institute, University Of Helsinki

Yves T. Falanga, PhD
University Of Massachusetts Medical School

Nicolas Gulati
The Rockefeller University

Kinjal Majumder
Washington University In St. Louis

Ioannis Politikos, MD
Beth Israel Deaconess Medical Center

Wade Iams, MD
Vanderbilt University Medical Center

Natalie Miller
University Of Washington School Of Medicine

Daniel Lowther
Yale University

David B. Page, PhD
Memorial Sloan-Kettering Cancer Center

Xiaoti Guo, PhD
North Shore-Lij Health System

Krithika Kodumudi, MD
Lee Moffitt Cancer Center

Vinay S Mahajan, MD, PhD
Center For Cancer Research, Massachusetts General Hospital

Catherine Meador
Vanderbilt University

Matthew Rausch, PhD
University Of Arizona College Of Medicine

Lauren Henderson, PhD
Boston Children's Hospital

David Bernal, PhD
Universidad Nacional De Colombia

Kirstin Heutinck, PhD
Academic Medical Center Amsterdam

Jamie Lynn Harden, MD
The Rockefeller University

Alan Watson, PhD
University Of Pittsburgh

Sven Malchow, PhD
University Of Chicago, Department Of Pathology

Marta Pasikowska
King's College London

Michela Bardini
Centro Ricerca Tettamanti University Of Milan Bicocca

Jennifer Sims, PhD
Columbia University Medical Center

Gaurav Gaiha, PhD
Ragon Institute Of Mgh, MIT & Harvard

Eric Allenspach, MD
Seattle Children's Hospital

Taizo Nakano, MD
Children's Hospital Colorado

Evaggelia Liaskou
University Of Birmingham, UK

Kyle K. Payne
Virginia Commonwealth University - Massey Cancer Center

Alison Smith
Tulane University

Patrick Hanley
Baylor College Of Medicine

YIA APPLICATION

Adaptive is dedicated to identifying new talent to help foster growth in the immunosequencing field. Every quarter, Adaptive Biotechnologies Corporation selects one or more applicants for our Young Investigator Award to receive a grant of up to $10,000 to use for sequencing to assist in his/her research in immunology.

Thank you for your interest in our Young Investigator Award program. The program supports post-doctoral fellows and pre-doctoral students pursuing exciting research projects in immunology and other related fields with potential implications towards advancement in immunology. Each quarter our goal is to select one or more qualifying applicants to receive a immunosequencing grant of up to $10,000 to assist with their research. The grant may be applied toward any of Adaptive's immunoSEQ® Assay products. In addition, our expert scientific advisors will provide experimental design and data analysis consultation. If you have any questions about the application process or would like to discuss your project or experimental design with one of our Scientific Liaisons, please contact scientificservices@adaptivebiotech.com.

To apply for our Young Investigator Award, complete and submit the form along with a one-page research proposal.

  • Research proposals can focus on any aspect of immunology
  • Proposals must describe a pilot study to profile either the human or mouse TCR or BCR repertoire
  • Proposal length is limited to one page
  • For further information on required qualifications, proposal details, and evaluation criteria, please see the appropriate sections at the bottom of this page

Applications for grants and all granted services must be for research purposes only, not for any diagnostic purposes.

Step 1 of 4

  • All fields are required
  • Applicants must be post-doctoral fellows, within 3 years after receipt of their first doctoral degree, with an appointment at an accredited university or research institution (exceptional pre-doctoral students pursuing qualified projects may also apply)
  • Applicants applying must have an MD, PhD, or equivalent advanced degree, and hold a position within the laboratory of a senior researcher or principal investigator who will serve as the applicant's mentor**
  • Applications from individuals holding faculty positions will not be accepted
  • There are no citizenship requirements for this program; Adaptive Biotechnologies welcomes applications from all qualified individuals from qualifying institutions worldwide

** It is expected that all applicants will write their application independently, with only limited assistance from their mentor

  • Research proposals may focus on any aspect of immunology or related fields with potential implications towards advancement in immunology
  • Proposals must describe a pilot study to profile either the human or mouse TCR or BCR repertoire
  • Proposal length is limited to one page
  • Proposals must be for research purposes only; Adaptive Biotechnologies does not currently offer public grants for clinical research projects (e.g. diagnostic or therapeutic trials

Proposals will be evaluated on: the innovative application of immunoSEQ Assays to the research concept, the soundness of the research design, and the value of the research to the field of immunology.

  • Winners receive a $10,000 grant for use towards the purchase of any immunoSEQ Assay immune cell sequencing Service or Kit 
  • Winners agree to cite Adaptive Biotechnologies in the methods section of any resulting publication
  • Winners also agree to be interviewed for, and possibly highlighted in, Adaptive's Researcher Profiles feature (with potential distribution via various promotional and media channels)
  • Winners must agree to submit data generated from their project to the immuneACCESS database within six months after its public release (i.e. any public reference to the data including, but not limited to, presentation via abstract, poster, or speaking engagement, press release, media interview, etc.)
  • Grant funds expire one year from date of award

All grant determinations and interpretations of the Young Investigator Award program will be made in the sole and absolute discretion of Adaptive Biotechnologies Corporation. The grant program may be revoked or terminated at any time for any reason, even after a grant notification has been issued. Winners will be required to sign or acknowledge a written grant agreement with Adaptive Biotechnologies Corporation as a condition for using the granted services.

You may not be eligible to receive the grant if you work for an institution that purchases diagnostic services from Adaptive Biotechnologies or if offering you the grant is otherwise prohibited under applicable law, which determination will be made by Adaptive Biotechnologies in its sole and absolute discretion. This grant receives support that may result in a report to the CMS Open Payments website under the Physician Payments Sunshine Act. The supporting companies are required to report the amount of the grant, the names of physicians who are awarded this grant, and the names of their institutions. This information may appear on the Open Payments website. More information about the Sunshine Act and CMS Open Payments program can be found here.